Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue (2009 - 2026)

Ionis Pharmaceuticals' Non-Current Deffered Revenue history runs 18 years deep, the most recent figure standing at $63.0 million for Q2 2026.

• In Q2 2026, Non-Current Deffered Revenue fell 49.61% year-over-year to $63.0 million; the TTM figure through Jun 2026 stood at $63.0 million (down 49.61% YoY), while the FY2025 annual figure was $92.0 million, down 41.21% from the prior year.
• Non-Current Deffered Revenue for Q2 2026 stood at $63.0 million, down from $75.7 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $333.1 million in Q1 2022, with the low at $63.0 million in Q2 2026.
• The 5-year median for Non-Current Deffered Revenue is $201.9 million (2024), against an average of $199.3 million.
• The sharpest annual moves came in 2023 and 2026: Non-Current Deffered Revenue decreased 15.4% in 2023, then sank 49.61% in 2026.
• Ionis Pharmaceuticals' Non-Current Deffered Revenue stood at $287.8 million in 2022, then declined by 16.19% to $241.2 million in 2023, then plunged by 35.11% to $156.5 million in 2024, then sank by 41.21% to $92.0 million in 2025, then plunged by 31.49% to $63.0 million in 2026.
• Business Quant data shows IONS's Non-Current Deffered Revenue at $63.0 million in Q2 2026, $75.7 million in Q1 2026, and $92.0 million in Q4 2025.